Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT103 in unresectable or surgically difficult giant cell tumor of bone
CTR20200072Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of narlumosbart in Giant Cell Tumor of Bone (GCTB), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Jun 2020; status: active.
02
Drugs
narlumosbart
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on CTR20200072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200072.